Cantor Fitzgerald Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by stock analysts at Cantor Fitzgerald from $405.00 to $525.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 29.68% from the stock’s current price. Cantor Fitzgerald also issued estimates for United Therapeutics’ FY2026 earnings at $31.56 EPS.

Other research analysts also recently issued reports about the stock. Bank of America lifted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Jefferies Financial Group lifted their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $438.85.

United Therapeutics Stock Performance

UTHR stock opened at $404.84 on Wednesday. The company has a market capitalization of $18.26 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 6.05 and a beta of 0.62. United Therapeutics has a one year low of $266.98 and a one year high of $436.95. The company’s 50 day moving average price is $316.32 and its two-hundred day moving average price is $307.23.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company’s revenue was up 11.7% compared to the same quarter last year. During the same period last year, the business posted $5.85 earnings per share. On average, research analysts predict that United Therapeutics will post 24.48 EPS for the current year.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 11,375 shares of United Therapeutics stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $397.41, for a total value of $4,520,538.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $397.23, for a total transaction of $1,588,920.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $51,639.90. This trade represents a 96.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 128,816 shares of company stock valued at $45,836,113 over the last quarter. 10.30% of the stock is owned by company insiders.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC bought a new stake in United Therapeutics in the second quarter valued at $29,000. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at $32,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.